期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 39, 期 1, 页码 11-15出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2011.08.018
关键词
Carbapenem; Ecology; Ertapenem; Pseudomonas; Stewardship; Susceptibility
资金
- Achaogen Inc.
- Basilea Pharmaceutica
- BioLine Therapeutics
- Cempra Pharmaceuticals Inc.
- Intercell AG
- Johnson and Johnson Pharmaceuticals
- Merck
- Cubist
- Ortho Pharmaceuticals
- Schering-Plough Pharmaceuticals
- Optimer Pharmaceuticals
- Theravance Inc.
- Pfizer Inc.
- Astellas Inc.
- Cerexa Inc.
- Impex Pharmaceuticals
- Novexel
- Novartis
- Clinical Microbiology Institute
- Genzyme
- NanoPacific Holdings Inc.
- Romark Laboratories LC
- ViroXis Corp.
- Warner Chilcott
- Avid-Biotics Corp.
- GLSynthesis Inc.
- Immunome Inc.
- Toltec Pharma LLC.
- Ortho-McNeil-Janssen
- Sanofi-Aventis
- Bayer-Schering Pharma
- AstraZeneca
- Cerexa
- Forest
- Johnson Johnson
- Pfizer
The group 2 carbapenems (imipenem, meropenem and, more recently, doripenem) have been a mainstay of treatment for patients with serious hospital infections caused by Pseudomonas aeruginosa, Enterobacteriaceae and other difficult-to-treat Gram-negative pathogens as well as mixed aerobic/anaerobic infections. When ertapenem, a group 1 carbapenem, was introduced, questions were raised about the potential for ertapenem to select for imipenem-and meropenem-resistant Pseudomonas. Results from ten clinical studies evaluating the effect of ertapenem use on the susceptibility of Pseudomonas to carbapenems have uniformly shown that ertapenem use does not result in decreased Pseudomonas susceptibility to these antipseudomonal carbapenems. Here we review these studies evaluating the evidence of how ertapenem use affects P. aeruginosa as well as provide considerations for ertapenem use in the context of institutional stewardship initiatives. (C) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据